NCT00096499: SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel |
|
|
| Completed | 2 | 40 | US | ispinesib, CK0238273, SB-715992, pharmacological study, pharmacological studies, laboratory biomarker analysis | National Cancer Institute (NCI) | Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer | 01/07 | | | |
